CD36 is also a worthwhile target for further investigation in the treatment of cardiovascular disease, as CD36 low molecular weight inhibitors reduced both atherosclerosis and metabolic abnormalities in a leptin and LDL receptor double knockout mouse model [85]. This evidence concerns the gene LDLR and atherosclerosis.